Ashley Gallagher is an assistant editor at Pharmacy Times®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.
California Pharmacy Knows Pharmacist-Physician Relationship Is Essential
CMD drugs understands that pharmacists are on the front lines with patients, necessitating strong communication with providers.
Study: PrEP Does Not Cause Shift in Vaginal Microbial Communities
Investigators examined the impact of daily oral tenofovir disoproxil fumarate in combination with emtricitabine to see the effect on the microbiota in South African women.
Therapies Targeting Capsid Proteins Show Promise for HIV-1
By targeting the viral conical core, these ARTs could disrupt the process of assembly and/or disassembly of the virus and result in its suppression.
Existing and Novel Treatments of Migraine Show Favorable Efficacy
Case studies highlight recent developments and trends in pharmacologic treatments for migraine.
COVID-19 Infection Increases Risk of Diabetes Diagnosis in Pediatric Patients
At month 6 post-COVID-19 infection, 123 patients received a diagnosis of type 1 diabetes (T1D) and only 72 were diagnosed with T1D at 6 months post-non-COVID-19 respiratory infection.
Changing Treatment Landscape for Chronic Migraine Shows Promise Over 5 Years
New treatments for chronic migraine have been increasing, with robust evidence for eptinezumab, erenumab, fremanezumab, galcanezumab, and onabotulinumtoxin A.
5 Modifiable Factors in Women with History of Gestational Diabetes Mellitus That Can Reduce the Risk of T2D
Investigators found that lifestyle changes such as a high-quality diet and regular exercise can lower the risk of type 2 diabetes in women with a history of gestational diabetes mellitus.
Merck’s Sotatercept Trial Results for Treatment of Adults With PAH Meet Primary Endpoint
The drug shows improvement in exercise capacity and key secondary outcomes compared with the placebo when added to background therapy for those with pulmonary arterial hypertension.
Heart Failure, Reduced Ejection Fraction Associated With Reduced Odds of IV Fluids
Investigators found that 25% of patients with heart failure with reduced ejection fraction received guideline-recommended intravenous fluids compared to 37% who did not have the condition.
Study: COVID-19, Hepatitis B Co-Infection Presents Greater Risk of Abnormal Liver Function
Investigators find that individuals with both conditions are more likely to develop severe disease than those in the control group.
IVIG Therapy May Fight Parvovirus-Associated Pure Red Cell Aplasia
Study results show that intravenous immunoglobulin therapy can help combat this type of PRCA in individuals with anemia.
Monjuvi Demonstrates Long-Term Efficacy for Individuals With R/R DLBCL
Study results show that the frequency of adverse events decreased after the patients transitioned from combination therapy to monotherapy.
Omidubicel Shows Clinical Benefit at 3 Years for Individuals With Hematologic Malignancies
The functional and physical well-being and other scores from the survey are more favorable for those who were treated with the therapy, investigators say.
Targeted Therapies Could Be Key to Treating Myelodysplastic Syndrome
IDH inhibitors show encouraging results in patients with myelodysplastic syndrome, but longer follow ups are needed in a larger patient population to confirm the results.
Study: Multivitamin Mineral Supplements Have Potential to Improve Cognition
In a study of 2262 individuals, investigators also found that cocoa extract had no effect on cognition.
Genomic Testing Framework for Chronic Kidney Disease Continues to Grow
Investigators combine research discovery with technological development to determine whether the role of genomics in nephrology should remain with subspecialists or be integrated into general nephrology.
Study Results Show Link Between Excess Weight and Risk of COVID-19, Lasting Disease
Analyses of more than 30,000 adults in the United Kingdom from 9 prospective cohort studies finds a high pre-pandemic BMI was associated with the infection.
Pharmacist Moms’ Dialogues Event Features Vaccination Updates, Addresses Hesitancy
Presentation by Chapman University dean highlights patient relations, staffing issues.
Sandoz’s Denosumab Meets Primary Endpoints in Phase 3 Trial
The biosimilar matches Prolia in efficacy, immunogenicity, pharmacodynamics, and pharmacokinetics in women who are postmenopausal with osteoporosis.
Tremfya Shows Higher Skin Clearance Rates With Earlier Treatment for Plaque Psoriasis
Janssen’s GUIDE data demonstrate that patients treated with guselkumab less than 2 years after disease onset vs later are more likely to achieve “super-responder” at week 20 through 28.
Pfizer Reports Positive Study Results for Pneumococcal Conjugate Vaccine in Infants in the EU
Pivotal top-line data demonstrate 20vPnC, if approved likely protects against 20 serotypes in 3-dose series and may offer the broadest serotype coverage of any PCV.
Imfinzi Plus Chemotherapy Shows Positive Results for Advanced Biliary Tract Cancer
Phase 3 TOPAZ-1 trial of AstraZeneca’s durvalumab demonstrates an improved overall survival benefit.
Olaparib With or Without Bevacizumab Shows Positive Results as Ovarian Cancer Treatment
AstraZeneca’s Lynparza in combination or as a monotherapy demonstrates meaningful survival benefit in long-term follow-up.
Study: 1 in 4 Families of Children With Acute Lymphoblastic Leukemia Face Food Insecurity
Receiving benefits from the SNAP program does not alleviate the issue, according to the analysis.
Study: Patients With Cancer Lack Access to LGBTQI+-Tailored Education Material
Analysis shows that individuals who are comfortable sharing their identities with providers are more likely to be satisfied with overall care.
Consumers Overpay for Generic Alternatives, Study Results Show
USC Analysis: although generics save US health care systems billions, PBMs jack up prices for employers, government, and patients.
FDA Approves Daxxify for Temporary Improvement of Moderate to Severe Frown Lines
DaxibotulinumtoxinA-lanm from Revance Therapeutics Inc is the first peptide-formulated neuromodulator with long-lasting results.
Experts Tackle Best Practices in Prophylactic Treatment of Hemophilia A
Panelists discuss pharmacist involvement in effective management, including disease burden and quality of life.
Cabozantinib, Nivolumab, Ipilimumab Combination Does Not Reach PFS
Triplet combination demonstrates a reduction in the risk of disease progression or death in individuals with previously untreated advanced intermediate- or poor-risk renal cell carcinoma.
NEJM Publishes Positive Phase 2 Results for Biogen’s Litifilimab Lupus Treatment
Part A results from the 2-part LILAC study show that the therapy significantly reduced disease activity based on active joint count in individuals compared with the placebo.
2 Clarke Drive Cranbury, NJ 08512